2022 has been a year for the books for Odyssey VC. From refreshing our brand to hosting thought leadership webinars and everything in between, it’s been a year for expanding in new and exciting ways as we continue to grow as a company. Read on as we take a look back at some of the most significant moments for Odyssey VC in the year of 2022.
Unveiling our new brand for Next Generation Life Sciences
We kicked off the year in earnest with the unveiling of our new brand, complete with new websites, a refreshed aesthetic, and a renewed focus on the growing number of digital transformation opportunities emerging in the industry. This overhaul included the launch of a new Odyssey VC website focused on clearly defined solutions and roadmaps that build a better way for our clients to grow, as well a new product website for our CompliantCloud.com platform for the deployment and maintenance of validated software applications. (www.compliantcloud.com)
We pride ourselves on driving innovation and change within the life sciences industry, and we wanted to embody these principles by honing our message and solidifying Odyssey VC as the expert partner, trusted to guide an industry on the precipice of an era of change and innovation.
Hosting “Possibilities & Practicalities of Cloud Adoption in Life Sciences”, our 2022 webinar series
Sharing vital information to aid the life sciences industry in embracing new technology and innovation was a key focus of our 2022 thought leadership webinar series, “Possibilities & Practicalities of Cloud Adoption in Life Sciences.”
Across four sessions held throughout the year, Odyssey’s team of experts came together to discuss and explore how we, as a community, can support the adoption of cloud technology in our industry. From the initial steps to building a successful regulated cloud adoption strategy to selecting fit-for-purpose cloud solutions and concluding with this month’s Part 4, covering Agile methodology that satisfies regulatory requirements, many fresh insights were shared and we are delighted with the reception to these webinars throughout the year.
Sharing our expertise through informative and diversifying content
Our industry-leading expertise in compliance and validation makes Odyssey VC well placed to share the latest industry insights, always with the goal of driving change and innovation in the typically slow to adapt life sciences industry. Apart from our 2022 thought leadership webinars, this year we shared vital information about Compliance as-a-Service, qualifying your infrastructure and more with a diverse range of content including product sheets, client stories, infographics (https://odysseyvc.com/infographic-odyssey-vcs-step-by-step-compliance-framework-for-life-sciences-and-their-saas-providers/ ) and an animated explainer video (Qualified Infrastructure as a Service (QIaaS) with Odyssey VC ).
Making this information accessible and digestible was one of our goals this year, and we’re looking forward to sharing an even broader range of content in the new year to shed light on the different facets of operating in this regulated industry.
Being selected as part of Enterprise Ireland’s €40 million Disruptive Technology Innovation Fund
In November it was announced that 11 innovative projects had been approved funding of up to €40 million in the first tranche of awards under the fourth round of the Disruptive Technologies Innovation Fund, with Odyssey VC announced as one of the companies involved in a consortium supporting FeelTect Ltd on the Heallntel project.
This project is focused on capturing multifaceted data to enable data-driven improvements to products and protocols associated with measuring and monitoring compression therapy and wound care. Odyssey VC’s CompliantCloud solution will support HealIntel’s software compliance requirements and facilitate the automation of activities necessary for cloud infrastructure and cloud application development in compliance with global healthcare regulations.
A key component in the success of technical innovation in life sciences is to support and accelerate the availability of compliant cloud solutions, and Odyssey VC are excited to continue to work with HealIntel to ensure their data security and software compliance requirements are fulfilled using industry regulations, guidelines, and best practices as this project evolves.
Award nominations & a team on the go!
With all the work going on throughout the year, it was heartening to take a breath and see the stellar efforts of our team recognised on a national level with two nominations at the Pharma Industry Awards.
Odyssey were nominated in the categories of “Pharma Contract Services Company of the Year” and “Pharma Project of the Year (Small)”. The former award honours an organisation offering contract services to the Irish pharmaceutical industry, while the latter recognises an outstanding project undertaken in Ireland’s Pharma industry over the past 12 months.
Although we didn’t win, we were thrilled to see our work nominated alongside some of the industry’s leading names and delighted to get the opportunity to rub shoulders with our peers at the ceremony in November.
We got plenty more opportunities to meet with industry peers on our travels throughout the year, as the team attended growth sessions in Berlin and Amsterdam. Working with consultants and connecting with market experts in these growing European hubs of innovation provided invaluable experiences and acted as another key step in our continued European expansion.
2022 has been a hectic yet pivotal year for Odyssey VC as we continue to go from strength to strength as a company, and we’re looking forward to more exciting developments and providing more insightful and dynamic content in the new year. In the meantime, we’d like to thank you for supporting us and engaging with our content throughout the year, as clients and followers alike. We wish you a restful holiday season and we’ll see you in 2023!
To find out more about our innovative solutions or to contact us with any questions or queries about what we can do for your business, click here.